150 related articles for article (PubMed ID: 11410024)
1. Comparison of a neural net-based QSAR algorithm (PCANN) with Hologram- and multiple linear regression-based QSAR approaches: application to 1,4-dihydropyridine-based calcium channel antagonists.
Viswanadhan VN; Mueller GA; Basak SC; Weinstein JN
J Chem Inf Comput Sci; 2001; 41(3):505-11. PubMed ID: 11410024
[TBL] [Abstract][Full Text] [Related]
2. Genetic algorithm applied to the selection of factors in principal component-artificial neural networks: application to QSAR study of calcium channel antagonist activity of 1,4-dihydropyridines (nifedipine analogous).
Hemmateenejad B; Akhond M; Miri R; Shamsipur M
J Chem Inf Comput Sci; 2003; 43(4):1328-34. PubMed ID: 12870926
[TBL] [Abstract][Full Text] [Related]
3. Application of ab initio theory to QSAR study of 1,4-dihydropyridine-based calcium channel blockers using GA-MLR and PC-GA-ANN procedures.
Hemmateenejad B; Safarpour MA; Miri R; Taghavi F
J Comput Chem; 2004 Sep; 25(12):1495-503. PubMed ID: 15224393
[TBL] [Abstract][Full Text] [Related]
4. QSAR study of 1,4-dihydropyridine calcium channel antagonists based on gene expression programming.
Si HZ; Wang T; Zhang KJ; Hu ZD; Fan BT
Bioorg Med Chem; 2006 Jul; 14(14):4834-41. PubMed ID: 16580211
[TBL] [Abstract][Full Text] [Related]
5. QSAR and classification study of 1,4-dihydropyridine calcium channel antagonists based on least squares support vector machines.
Yao X; Liu H; Zhang R; Liu M; Hu Z; Panaye A; Doucet JP; Fan B
Mol Pharm; 2005; 2(5):348-56. PubMed ID: 16196487
[TBL] [Abstract][Full Text] [Related]
6. Quantitative structure-activity relationship and quantitative structure-pharmacokinetics relationship of 1,4-dihydropyridines and pyridines as multidrug resistance modulators.
Zhou XF; Shao Q; Coburn RA; Morris ME
Pharm Res; 2005 Dec; 22(12):1989-96. PubMed ID: 16158213
[TBL] [Abstract][Full Text] [Related]
7. Comparison between neural networks (NN) and principal component analysis (PCA): structure activity relationships of 1,4-dihydropyridine calcium channel antagonists (nifedipine analogues).
Takahata Y; Costa MC; Gaudio AC
J Chem Inf Comput Sci; 2003; 43(2):540-4. PubMed ID: 12653519
[TBL] [Abstract][Full Text] [Related]
8. Modeling calcium channel antagonistic activity of dihydropyridine derivatives using QTMS indices analyzed by GA-PLS and PC-GA-PLS.
Mohajeri A; Hemmateenejad B; Mehdipour A; Miri R
J Mol Graph Model; 2008 Apr; 26(7):1057-65. PubMed ID: 17959402
[TBL] [Abstract][Full Text] [Related]
9. Quantitative structure-activity relationship study of recently synthesized 1,4-dihydropyridine calcium channel antagonists. Application of the Hansch analysis method.
Hemmateenejad B; Miri R; Akhond M; Shamsipur M
Arch Pharm (Weinheim); 2002 Dec; 335(10):472-80. PubMed ID: 12506395
[TBL] [Abstract][Full Text] [Related]
10. GA strategy for variable selection in QSAR studies: GA-based PLS analysis of calcium channel antagonists.
Hasegawa K; Miyashita Y; Funatsu K
J Chem Inf Comput Sci; 1997; 37(2):306-10. PubMed ID: 9157101
[TBL] [Abstract][Full Text] [Related]
11. The learned symmetry concept in revealing quantitative structure-activity relationships with artificial neural networks.
Baskin II; Halberstam NM; Mukhina TV; Palyulin VA; Zefirov NS
SAR QSAR Environ Res; 2001; 12(4):401-16. PubMed ID: 11769122
[TBL] [Abstract][Full Text] [Related]
12. Docking and QSAR Studies of 1,4-Dihydropyridine Derivatives as Anti- Cancer Agent.
Mollazadeh S; Shamsara J; Iman M; Hadizadeh F
Recent Pat Anticancer Drug Discov; 2017; 12(2):174-185. PubMed ID: 28137213
[TBL] [Abstract][Full Text] [Related]
13. SMILES-based QSAR models for the calcium channel-antagonistic effect of 1,4-dihydropyridines.
Veselinović AM; Milosavljević JB; Toropov AA; Nikolić GM
Arch Pharm (Weinheim); 2013 Feb; 346(2):134-9. PubMed ID: 23280520
[TBL] [Abstract][Full Text] [Related]
14. Application of electron conformational-genetic algorithm approach to 1,4-dihydropyridines as calcium channel antagonists: pharmacophore identification and bioactivity prediction.
Geçen N; Sarıpınar E; Yanmaz E; Sahin K
J Mol Model; 2012 Jan; 18(1):65-82. PubMed ID: 21451963
[TBL] [Abstract][Full Text] [Related]
15. Molecular modelling and QSAR analysis of some structurally diverse N-type calcium channel blockers.
Mungalpara J; Pandey A; Jain V; Mohan CG
J Mol Model; 2010 Apr; 16(4):629-44. PubMed ID: 19802636
[TBL] [Abstract][Full Text] [Related]
16. Different effects of dihydropyridine calcium channel antagonists on CYP3A4 enzyme of human liver microsomes.
Xia Z; Wang M; Zou S; Chen R
Eur J Drug Metab Pharmacokinet; 2012 Sep; 37(3):211-6. PubMed ID: 22161476
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, QSAR and calcium channel antagonist activity of new 1,4-dihydropyridine derivatives containing 1-methyl-4,5-dichloroimidazolyl substituents.
Hosseini M; Miri R; Amini M; Mirkhani H; Hemmateenejad B; Ghodsi S; Alipour E; Shafiee A
Arch Pharm (Weinheim); 2007 Oct; 340(10):549-56. PubMed ID: 17849444
[TBL] [Abstract][Full Text] [Related]
18. QSAR, diagnostic statistics and molecular modelling of 1,4-dihydropyridine calcium antagonists: a difficult road ahead.
Mager PP; Coburn RA; Solo AJ; Triggle DJ; Rothe H
Drug Des Discov; 1992 Jul; 8(4):273-89. PubMed ID: 1445993
[TBL] [Abstract][Full Text] [Related]
19. Comparative QSAR studies of two series of 1,4-dihydropyridines as slow calcium channel blockers.
Wikel JH; Bemis KG; Kurz K; Denney ML; Main BW; Moore RA; Smith T; Shingleton L; Holland DR
Drug Des Discov; 1994 Jan; 11(1):1-14. PubMed ID: 8068815
[TBL] [Abstract][Full Text] [Related]
20. Quantitative structure-activity relationship studies on some series of calcium channel blockers.
Gupta SP; Veerman A; Bagaria P
Mol Divers; 2004; 8(4):357-63. PubMed ID: 15612639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
